Published in Am J Trop Med Hyg on August 01, 2009
OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet Genomics (2013) 1.02
Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob Agents Chemother (2014) 0.84
Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis. PLoS One (2015) 0.82
Comparative Proteomics of Activated THP-1 Cells Infected with Mycobacterium tuberculosis Identifies Putative Clearance Biomarkers for Tuberculosis Treatment. PLoS One (2015) 0.77
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. Antimicrob Agents Chemother (2014) 0.76
The Influence of Mining and Human Immunodeficiency Virus Infection Among Patients Admitted for Retreatment of Tuberculosis in Northern Tanzania. Am J Trop Med Hyg (2015) 0.75
The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ (2003) 11.82
An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med (2006) 5.02
Multi-country analysis of the effects of diarrhoea on childhood stunting. Int J Epidemiol (2008) 4.46
Enteric infections, diarrhea, and their impact on function and development. J Clin Invest (2008) 3.23
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86
Malnutrition as an enteric infectious disease with long-term effects on child development. Nutr Rev (2008) 2.84
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med (2003) 2.56
Clinical practice. Acute infectious diarrhea. N Engl J Med (2004) 2.47
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med (2004) 2.40
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis (2009) 2.36
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis (2005) 2.34
Intestinal barrier function and weight gain in malnourished children taking glutamine supplemented enteral formula. J Pediatr Gastroenterol Nutr (2005) 2.25
Early childhood diarrhea is associated with diminished cognitive function 4 to 7 years later in children in a northeast Brazilian shantytown. Am J Trop Med Hyg (2002) 2.22
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med (2005) 2.21
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2006) 2.18
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother (2011) 1.99
The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med (2012) 1.94
Enteroaggregative Escherichia coli (EAEC) impairs growth while malnutrition worsens EAEC infection: a novel murine model of the infection malnutrition cycle. J Infect Dis (2010) 1.90
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med (2006) 1.90
Fecal markers of intestinal inflammation and permeability associated with the subsequent acquisition of linear growth deficits in infants. Am J Trop Med Hyg (2012) 1.83
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2012) 1.83
Early childhood diarrhea predicts impaired school performance. Pediatr Infect Dis J (2006) 1.71
Cryptosporidiosis: epidemiology and impact. Microbes Infect (2002) 1.71
Updating the DALYs for diarrhoeal disease. Trends Parasitol (2002) 1.66
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med (2013) 1.65
Diarrhea and reduced levels of antiretroviral drugs: improvement with glutamine or alanyl-glutamine in a randomized controlled trial in northeast Brazil. Clin Infect Dis (2004) 1.65
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother (2012) 1.63
Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis (2005) 1.61
Childhood stunting: measuring and stemming the staggering costs of inadequate water and sanitation. Lancet (2004) 1.56
The impoverished gut--a triple burden of diarrhoea, stunting and chronic disease. Nat Rev Gastroenterol Hepatol (2012) 1.53
Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis (2009) 1.49
Magnitude and impact of diarrheal diseases. Arch Med Res (2002) 1.49
Heavy cryptosporidial infections in children in northeast Brazil: comparison of Cryptosporidium hominis and Cryptosporidium parvum. Trans R Soc Trop Med Hyg (2006) 1.49
Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med (2008) 1.47
Reducing stunting among children: the potential contribution of diagnostics. Nature (2006) 1.44
Prolonged episodes of acute diarrhea reduce growth and increase risk of persistent diarrhea in children. Gastroenterology (2010) 1.41
Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother (2010) 1.40
APOE4 protects the cognitive development in children with heavy diarrhea burdens in Northeast Brazil. Pediatr Res (2004) 1.39
PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother (2010) 1.38
Implications of acquired environmental enteric dysfunction for growth and stunting in infants and children living in low- and middle-income countries. Food Nutr Bull (2013) 1.38
Cholera--still teaching hard lessons. N Engl J Med (2006) 1.35
Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs (2014) 1.34
American visceral leishmaniasis (kala-azar) in hospitalized children from an endemic area. J Pediatr (Rio J) (2005) 1.33
Wasting is associated with stunting in early childhood. J Nutr (2012) 1.33
Mechanism of Clostridium difficile toxin A-induced apoptosis in T84 cells. J Infect Dis (2002) 1.32
Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis (2009) 1.32
Pediatric diarrhea in southern Ghana: etiology and association with intestinal inflammation and malnutrition. Am J Trop Med Hyg (2010) 1.31
Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy (2002) 1.31
Giardia duodenalis assemblage, clinical presentation and markers of intestinal inflammation in Brazilian children. Trans R Soc Trop Med Hyg (2008) 1.30
A lion in our village--the unconscionable tragedy of cholera in Africa. N Engl J Med (2009) 1.27
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother (2007) 1.26
Detection and quantification of Cryptosporidium in HCT-8 cells and human fecal specimens using real-time polymerase chain reaction. Am J Trop Med Hyg (2007) 1.25
Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother (2009) 1.24
Real-time PCR detection and speciation of Cryptosporidium infection using Scorpion probes. J Med Microbiol (2006) 1.23
Diarrhea in early childhood: short-term association with weight and long-term association with length. Am J Epidemiol (2013) 1.22
Paediatric use of second-line anti-tuberculosis agents: a review. Tuberculosis (Edinb) (2011) 1.19
Caspase and bid involvement in Clostridium difficile toxin A-induced apoptosis and modulation of toxin A effects by glutamine and alanyl-glutamine in vivo and in vitro. Infect Immun (2006) 1.18
Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2010) 1.17
The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis (2005) 1.17
Short report: asymptomatic Cryptosporidium hominis infection among human immunodeficiency virus-infected patients in Tanzania. Am J Trop Med Hyg (2005) 1.17
Probiotics, enteric and diarrheal diseases, and global health. Gastroenterology (2010) 1.16
Cryptosporidium infection causes undernutrition and, conversely, weanling undernutrition intensifies infection. J Parasitol (2008) 1.16
Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett (2008) 1.15
Role of apolipoprotein E4 in protecting children against early childhood diarrhea outcomes and implications for later development. Med Hypotheses (2006) 1.14
Limitations in verbal fluency following heavy burdens of early childhood diarrhea in Brazilian shantytown children. Child Neuropsychol (2005) 1.14
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother (2008) 1.14
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med (2011) 1.13
Novel in vitro and in vivo models and potential new therapeutics to break the vicious cycle of Cryptosporidium infection and malnutrition. J Infect Dis (2012) 1.09
Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother (2009) 1.08
AIDS-associated diarrhea and wasting in Northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of Cryptosporidium parvum. Braz J Infect Dis (2003) 1.07
Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy (2009) 1.06
Clostridium difficile toxin A induces intestinal epithelial cell apoptosis and damage: role of Gln and Ala-Gln in toxin A effects. Dig Dis Sci (2005) 1.06
Cryptosporidium-malnutrition interactions: mucosal disruption, cytokines, and TLR signaling in a weaned murine model. J Parasitol (2011) 1.06
Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis. Braz J Infect Dis (2006) 1.05
Does childhood diarrhea influence cognition beyond the diarrhea-stunting pathway? PLoS One (2012) 1.05
Alanyl-glutamine hastens morphologic recovery from 5-fluorouracil-induced mucositis in mice. Nutrition (2004) 1.04
Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model. Antimicrob Agents Chemother (2012) 1.03
Early childhood growth failure and the developmental origins of adult disease: do enteric infections and malnutrition increase risk for the metabolic syndrome? Nutr Rev (2012) 1.02
Global impact of diarrheal diseases that are sampled by travelers: the rest of the hippopotamus. Clin Infect Dis (2005) 1.02